1. Home
  2. MLYS vs NRK Comparison

MLYS vs NRK Comparison

Compare MLYS & NRK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Mineralys Therapeutics Inc.

MLYS

Mineralys Therapeutics Inc.

HOLD

Current Price

$36.99

Market Cap

3.1B

Sector

Health Care

ML Signal

HOLD

Logo Nuveen New York AMT-Free Quality Municipal Income Fund

NRK

Nuveen New York AMT-Free Quality Municipal Income Fund

HOLD

Current Price

$10.08

Market Cap

878.5M

Sector

Finance

ML Signal

HOLD

Company Overview

Basic Information
Metric
MLYS
NRK
Founded
2019
2002
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Trusts Except Educational Religious and Charitable
Sector
Health Care
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
3.1B
878.5M
IPO Year
2023
N/A

Fundamental Metrics

Financial Performance
Metric
MLYS
NRK
Price
$36.99
$10.08
Analyst Decision
Strong Buy
Analyst Count
6
0
Target Price
$46.40
N/A
AVG Volume (30 Days)
1.6M
187.3K
Earning Date
11-10-2025
01-01-0001
Dividend Yield
N/A
4.10%
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$8.24
$8.95
52 Week High
$47.65
$11.09

Technical Indicators

Market Signals
Indicator
MLYS
NRK
Relative Strength Index (RSI) 40.09 41.65
Support Level $35.77 $10.03
Resistance Level $44.13 $10.15
Average True Range (ATR) 1.93 0.06
MACD -0.64 -0.01
Stochastic Oscillator 14.95 21.52

Price Performance

Historical Comparison
MLYS
NRK

About MLYS Mineralys Therapeutics Inc.

Mineralys Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing medicines to target diseases driven by abnormally elevated aldosterone. The company's product candidate, lorundrostat, is a proprietary, orally administered, selective aldosterone synthase inhibitor, that is initially developed for the treatment of patients with uncontrolled hypertension, defined as individuals who are unable to achieve BP of below 130/80 mmHg despite taking two or more lines of antihypertensive medication or resistant hypertension, typically including a diuretic.

About NRK Nuveen New York AMT-Free Quality Municipal Income Fund

Nuveen New York AMT-Free Quality Municipal Income Fund is a closed-end investment company. The Fund seeks to provide current income exempt from regular federal, New York State, and New York City income taxes, and from the federal alternative minimum tax for individuals, while enhancing portfolio value relative to the municipal bond market by investing in tax-exempt municipal bonds considered underrated, undervalued, or from undervalued municipal market sectors. It may invest in municipal securities such as lease obligations and certificates of participation, which provide an undivided interest in pools of municipal leases or installment purchase agreements.

Share on Social Networks: